Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial.
Clinical takeaway Cangrelor produced more frequent effective platelet inhibition in the tested subset, but clinical non-inferiority to crushed ticagrelor was not established. The laboratory result does not establish a clinical benefit.